Haemonetics Corporation (HAE) 10-Year Financial Performance & Capital Metrics

HAE • • Industrial / General

HealthcareMedical InstrumentsInfusion & Drug Delivery SystemsIV Therapy & Access Products

AboutHaemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Show more

Revenue $1.36B +4.0%
EBITDA $331M +30.5%
Net Income $168M +42.6%
EPS (Diluted) 3.31 +44.5%
Gross Margin 57.21% +5.2%
EBITDA Margin 24.3% +25.5%
Operating Margin 16.3% +29.4%
Net Margin 12.32% +37.2%
ROE 18.83% +42.4%
ROIC 10% +16.8%
Debt/Equity 1.49 +77.3%
Interest Coverage 22.76 +79.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 17.0%
✓Good 3Y average ROE of 15.6%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.1%

5Y6.6%

3Y11.07%

TTM-2.45%

Profit (Net Income) CAGR

10Y25.8%

5Y16.99%

3Y56.94%

TTM35.84%

EPS CAGR

10Y26.32%

5Y17.47%

3Y57.95%

TTM41.91%

ROCE

10Y Avg6.3%

5Y Avg8.7%

3Y Avg10.35%

Latest11.77%

Peer Comparison

IV Therapy & Access Products

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TFXTeleflex Incorporated	4.62B	104.61	70.68	2.45%	-10.28%	-8.58%	11.02%	0.41
HAEHaemonetics Corporation	3.46B	74.00	22.36	3.95%	12.67%	19.81%	4.11%	1.49
ICUIICU Medical, Inc.	3.83B	155.12	-32.12	5.44%	-0.32%	-0.35%	3.26%	0.84

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	908.83M	886.12M	903.92M	967.58M	988.48M	870.46M	993.2M	1.17B	1.31B	1.36B
Revenue Growth %	-0%	-0.02%	0.02%	0.07%	0.02%	-0.12%	0.14%	0.18%	0.12%	0.04%
Cost of Goods Sold+	502.92M	507.62M	492.01M	550.04M	500.66M	442.02M	462.43M	545.79M	597.14M	582.28M
COGS % of Revenue	0.55%	0.57%	0.54%	0.57%	0.51%	0.51%	0.47%	0.47%	0.46%	0.43%
Gross Profit+	405.91M	378.49M	411.91M	417.54M	487.82M	428.45M	530.77M	622.87M	711.91M	778.55M
Gross Margin %	0.45%	0.43%	0.46%	0.43%	0.49%	0.49%	0.53%	0.53%	0.54%	0.57%
Gross Profit Growth %	-0.07%	-0.07%	0.09%	0.01%	0.17%	-0.12%	0.24%	0.17%	0.14%	0.09%
Operating Expenses+	449.86M	397.88M	355.75M	333.99M	384.47M	338.7M	450.02M	466.84M	547.03M	556.73M
OpEx % of Revenue	0.49%	0.45%	0.39%	0.35%	0.39%	0.39%	0.45%	0.4%	0.42%	0.41%
Selling, General & Admin	317.22M	301.73M	316.52M	298.28M	266.33M	263.83M	332.2M	373.95M	420.82M	422.05M
SG&A % of Revenue	0.35%	0.34%	0.35%	0.31%	0.27%	0.3%	0.33%	0.32%	0.32%	0.31%
Research & Development	55.87M	47.26M	39.23M	35.71M	39.08M	40.66M	55.2M	58.63M	63.03M	69.42M
R&D % of Revenue	0.06%	0.05%	0.04%	0.04%	0.04%	0.05%	0.06%	0.05%	0.05%	0.05%
Other Operating Expenses	76.77M	48.89M	0	0	79.05M	34.21M	62.62M	34.26M	63.18M	65.26M
Operating Income+	-43.94M	-19.38M	56.16M	83.55M	103.35M	89.75M	80.75M	156.03M	164.88M	221.82M
Operating Margin %	-0.05%	-0.02%	0.06%	0.09%	0.1%	0.1%	0.08%	0.13%	0.13%	0.16%
Operating Income Growth %	-2.08%	0.56%	3.9%	0.49%	0.24%	-0.13%	-0.1%	0.93%	0.06%	0.35%
EBITDA+	41.07M	64.65M	145.4M	192.96M	195.54M	174.03M	167.3M	240.84M	253.5M	330.7M
EBITDA Margin %	0.05%	0.07%	0.16%	0.2%	0.2%	0.2%	0.17%	0.21%	0.19%	0.24%
EBITDA Growth %	-0.68%	0.57%	1.25%	0.33%	0.01%	-0.11%	-0.04%	0.44%	0.05%	0.3%
D&A (Non-Cash Add-back)	85.01M	84.03M	89.25M	109.42M	92.19M	84.29M	86.55M	84.81M	88.61M	108.89M
EBIT	43.73M	39.21M	64.16M	83.55M	165.75M	100.1M	105.17M	167.2M	206.84M	247.1M
Net Interest Income+	-9.47M	-8.1M	-4.53M	-9.91M	-16.2M	-16.83M	-17.12M	-14.63M	-13.02M	-9.75M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	9.47M	8.1M	4.53M	9.91M	16.2M	16.83M	17.12M	14.63M	13.02M	9.75M
Other Income/Expense	-9.47M	-8.1M	3.48M	-9.91M	-16.2M	-16.83M	-17.12M	-14.63M	-13.02M	-9.75M
Pretax Income+	-53.42M	-27.48M	59.63M	73.63M	87.15M	72.91M	63.63M	141.4M	151.87M	212.07M
Pretax Margin %	-0.06%	-0.03%	0.07%	0.08%	0.09%	0.08%	0.06%	0.12%	0.12%	0.16%
Income Tax+	2.16M	-1.21M	14.06M	18.61M	10.63M	-6.56M	20.25M	26M	34.31M	44.39M
Effective Tax Rate %	1.04%	0.96%	0.76%	0.75%	0.88%	1.09%	0.68%	0.82%	0.77%	0.79%
Net Income+	-55.62M	-26.27M	45.57M	55.02M	76.53M	79.47M	43.38M	115.4M	117.56M	167.68M
Net Margin %	-0.06%	-0.03%	0.05%	0.06%	0.08%	0.09%	0.04%	0.1%	0.09%	0.12%
Net Income Growth %	-4.29%	0.53%	2.73%	0.21%	0.39%	0.04%	-0.45%	1.66%	0.02%	0.43%
Net Income (Continuing)	-55.58M	-26.27M	45.57M	55.02M	76.53M	79.47M	43.38M	115.4M	117.56M	167.68M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.09	-0.51	0.85	1.04	1.48	1.55	0.84	2.24	2.29	3.31
EPS Growth %	-4.41%	0.53%	2.67%	0.22%	0.42%	0.05%	-0.46%	1.67%	0.02%	0.45%
EPS (Basic)	-1.09	-0.51	0.86	1.07	1.51	1.57	0.85	2.27	2.32	3.31
Diluted Shares Outstanding	50.91M	51.52M	53.5M	52.94M	51.81M	51.29M	51.35M	51.42M	51.4M	50.73M
Basic Shares Outstanding	50.91M	51.51M	52.76M	51.53M	50.69M	50.69M	51.05M	50.78M	50.71M	50.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	487.2M	510.03M	521.18M	576.12M	603.64M	693.55M	756.03M	769.72M	768.9M	934.98M
Cash & Short-Term Investments	115.12M	139.56M	180.17M	169.35M	137.31M	192.31M	259.5M	284.47M	178.8M	306.76M
Cash Only	115.12M	139.56M	180.17M	169.35M	137.31M	192.31M	259.5M	284.47M	178.8M	306.76M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	157.09M	152.68M	151.23M	185.03M	165.21M	127.56M	159.38M	179.14M	206.56M	202.66M
Days Sales Outstanding	63.09	62.89	61.06	69.8	61	53.49	58.57	55.95	57.6	54.36
Inventory	186.14M	176.93M	160.8M	194.34M	270.28M	322.61M	293.03M	259.38M	317.2M	365.14M
Days Inventory Outstanding	135.1	127.22	119.29	128.96	197.04	266.4	231.29	173.46	193.89	228.89
Other Current Assets	28.84M	40.85M	28.98M	27.41M	0	0	0	46.73M	66.34M	60.41M
Total Non-Current Assets+	829.9M	728.68M	716.16M	698.65M	663.47M	1.13B	1.1B	1.17B	1.43B	1.52B
Property, Plant & Equipment	337.63M	323.86M	332.16M	343.98M	253.4M	217.56M	258.48M	310.88M	366.63M	284.05M
Fixed Asset Turnover	2.69x	2.74x	2.72x	2.81x	3.90x	4.00x	3.84x	3.76x	3.57x	4.79x
Goodwill	267.84M	210.84M	211.4M	210.82M	210.65M	466.44M	467.29M	466.23M	565.08M	604.27M
Intangible Assets	204.46M	177.54M	156.59M	127.69M	133.11M	365.48M	310.26M	275.77M	406.12M	455.74M
Long-Term Investments	-7.05M	-3.99M	-3.96M	-4.36M	0	0	0	0	0	0
Other Non-Current Assets	19.97M	16.44M	16.02M	16.16M	62.38M	70.88M	63.2M	106.97M	81.12M	164.11M
Total Assets+	1.32B	1.24B	1.24B	1.27B	1.27B	1.82B	1.86B	1.93B	2.2B	2.45B
Asset Turnover	0.69x	0.72x	0.73x	0.76x	0.78x	0.48x	0.53x	0.60x	0.60x	0.56x
Asset Growth %	-0.11%	-0.06%	-0%	0.03%	-0.01%	0.44%	0.02%	0.04%	0.13%	0.12%
Total Current Liabilities+	184.71M	211.18M	384.7M	235.76M	274.82M	253.5M	442.27M	251.82M	300.38M	578.11M
Accounts Payable	39.67M	42.97M	55.27M	63.36M	50.73M	50.29M	58.37M	63.93M	73.36M	67M
Days Payables Outstanding	28.79	30.9	41	42.05	36.98	41.53	46.07	42.75	44.84	42
Short-Term Debt	43.47M	61.02M	194.26M	27.67M	76.98M	17.02M	214.15M	11.78M	10.23M	303.56M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	35.68M	32.76M	34.51M	55.8M	44.92M	80.95M	87.2M	81.42M	104.85M	104.78M
Current Ratio	2.64x	2.42x	1.35x	2.44x	2.20x	2.74x	1.71x	3.06x	2.56x	1.62x
Quick Ratio	1.63x	1.58x	0.94x	1.62x	1.21x	1.46x	1.05x	2.03x	1.50x	0.99x
Cash Conversion Cycle	169.39	159.21	139.35	156.71	221.06	278.36	243.79	186.66	206.64	241.25
Total Non-Current Liabilities+	412.42M	287.92M	100.21M	371.14M	405.18M	834.76M	668.04M	865.01M	935.25M	1.05B
Long-Term Debt	364.53M	253.63M	59.42M	322.45M	305.51M	690.59M	559.44M	754.1M	797.56M	921.23M
Capital Lease Obligations	0	0	0	0	52.01M	62.96M	0	0	0	0
Deferred Tax Liabilities	23.66M	13.74M	9.38M	22.8M	14M	43.83M	28.73M	36.2M	62.64M	62.58M
Other Non-Current Liabilities	26.11M	22.18M	34.26M	28.78M	33.65M	37.38M	79.88M	74.72M	75.04M	68.19M
Total Liabilities	597.13M	499.1M	484.91M	606.9M	680M	1.09B	1.11B	1.12B	1.24B	1.63B
Total Debt+	408M	314.65M	253.68M	350.12M	441.81M	778.28M	780.78M	765.89M	807.79M	1.22B
Net Debt	292.88M	175.08M	73.51M	180.77M	304.5M	585.97M	521.29M	481.42M	628.99M	918.02M
Debt / Equity	0.57x	0.43x	0.34x	0.52x	0.75x	1.06x	1.04x	0.94x	0.84x	1.49x
Debt / EBITDA	9.93x	4.87x	1.74x	1.81x	2.26x	4.47x	4.67x	3.18x	3.19x	3.70x
Net Debt / EBITDA	7.13x	2.71x	0.51x	0.94x	1.56x	3.37x	3.12x	2.00x	2.48x	2.78x
Interest Coverage	-4.64x	-2.39x	12.41x	8.43x	6.38x	5.33x	4.72x	10.67x	12.67x	22.76x
Total Equity+	719.98M	739.61M	752.43M	667.87M	587.11M	731.67M	749.42M	818M	959.96M	820.84M
Equity Growth %	-0.13%	0.03%	0.02%	-0.11%	-0.12%	0.25%	0.02%	0.09%	0.17%	-0.14%
Book Value per Share	14.14	14.35	14.06	12.62	11.33	14.26	14.59	15.91	18.68	16.18
Total Shareholders' Equity	719.98M	739.61M	752.43M	667.87M	587.11M	731.67M	749.42M	818M	959.96M	820.84M
Common Stock	509K	523K	523K	510K	503K	509K	511K	504K	508K	482K
Retained Earnings	316.18M	289.92M	266.94M	161.42M	78.51M	157.98M	202.39M	253.17M	360.46M	352.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-35.04M	-32.87M	-18.99M	-30.38M	-45.13M	-29.55M	-25.95M	-30.38M	-35.63M	-55.08M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	121.86M	159.74M	220.35M	159.28M	158.22M	108.81M	172.26M	273.06M	181.75M	181.72M
Operating CF Margin %	0.13%	0.18%	0.24%	0.16%	0.16%	0.12%	0.17%	0.23%	0.14%	0.13%
Operating CF Growth %	-0.04%	0.31%	0.38%	-0.28%	-0.01%	-0.31%	0.58%	0.59%	-0.33%	-0%
Net Income	-55.62M	-26.27M	45.57M	55.02M	76.53M	79.47M	43.38M	115.4M	117.56M	167.68M
Depreciation & Amortization	90.03M	89.73M	89.25M	109.42M	110.29M	84.29M	97.75M	93.31M	97.22M	115.59M
Stock-Based Compensation	6.95M	9.15M	13.03M	17.19M	20.45M	25.52M	24.36M	25.58M	0	29.64M
Deferred Taxes	-1.04M	-6.8M	-5.83M	13.35M	-6.96M	-19.87M	5.01M	4.78M	-11.04M	-5.22M
Other Non-Cash Items	101.65M	94.91M	1.85M	27.05M	42.47M	-919K	16.95M	8.48M	52.72M	-24M
Working Capital Changes	-20.11M	-983K	76.49M	-62.75M	-84.56M	-59.68M	-15.18M	25.5M	-74.7M	-101.96M
Change in Receivables	-10.33M	3.15M	5.09M	-38.06M	18.86M	44.12M	-34.97M	-24.42M	-24.19M	6.96M
Change in Inventory	12.78M	-1.55M	14.38M	-39.32M	-84.72M	-38.91M	24.31M	30.75M	-60.06M	-64.7M
Change in Payables	-30.24M	21.07M	41.4M	17.74M	-17.31M	0	0	39.82M	44.58M	0
Cash from Investing+	-104.77M	-73.31M	-63.04M	-116.15M	-57.18M	-425.44M	-86.34M	-143.79M	-322.39M	-161.9M
Capital Expenditures	-102.41M	-76.14M	-74.8M	-118.96M	-48.76M	-37.04M	-96.51M	-110.19M	-66.3M	-39.28M
CapEx % of Revenue	0.11%	0.09%	0.08%	0.12%	0.05%	0.04%	0.1%	0.09%	0.05%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-101.77M	2.82M	2.76M	2.81M	16.77M	1.81M	2.02M	1.61M	0	-15M
Cash from Financing+	-62.62M	-60.41M	-120.64M	-50.63M	-131.21M	367.45M	-15.75M	-100.36M	38.16M	108.82M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-943K	0	40.34M	13.45M	11.92M	-50.67M	1.75M	-15.74M	-6.81M	-113.49M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	19.46M	83.6M	145.55M	40.32M	109.46M	71.77M	75.75M	162.87M	115.45M	142.45M
FCF Margin %	0.02%	0.09%	0.16%	0.04%	0.11%	0.08%	0.08%	0.14%	0.09%	0.1%
FCF Growth %	2.92%	3.3%	0.74%	-0.72%	1.71%	-0.34%	0.06%	1.15%	-0.29%	0.23%
FCF per Share	0.38	1.62	2.72	0.76	2.11	1.40	1.48	3.17	2.25	2.81
FCF Conversion (FCF/Net Income)	-2.19x	-6.08x	4.84x	2.90x	2.07x	1.37x	3.97x	2.37x	1.55x	1.08x
Interest Paid	8.51M	7.85M	7.66M	13.12M	12.54M	7.82M	6.19M	13.59M	0	16.53M
Taxes Paid	7.83M	6.96M	9.08M	8.21M	11.51M	12.49M	24.3M	17.97M	0	49.29M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-7.19%	-3.6%	6.11%	7.75%	12.2%	12.05%	5.86%	14.72%	13.22%	18.83%
Return on Invested Capital (ROIC)	-3.13%	-1.51%	4.84%	7.48%	8.91%	6.09%	4.68%	9.11%	8.56%	10%
Gross Margin	44.66%	42.71%	45.57%	43.15%	49.35%	49.22%	53.44%	53.3%	54.38%	57.21%
Net Margin	-6.12%	-2.96%	5.04%	5.69%	7.74%	9.13%	4.37%	9.87%	8.98%	12.32%
Debt / Equity	0.57x	0.43x	0.34x	0.52x	0.75x	1.06x	1.04x	0.94x	0.84x	1.49x
Interest Coverage	-4.64x	-2.39x	12.41x	8.43x	6.38x	5.33x	4.72x	10.67x	12.67x	22.76x
FCF Conversion	-2.19x	-6.08x	4.84x	2.90x	2.07x	1.37x	3.97x	2.37x	1.55x	1.08x
Revenue Growth	-0.17%	-2.5%	2.01%	7.04%	2.16%	-11.94%	14.1%	17.67%	12.01%	3.95%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Hospital	124.61M	-	-	196.54M	198.42M	216.58M	329.43M	378.11M	445.98M	564.27M
Hospital Growth	-	-	-	-	0.96%	9.15%	52.10%	14.78%	17.95%	26.52%
Plasma	-	410.73M	435.96M	501.84M	537.23M	414.27M	427.61M	563.73M	565.4M	535.43M
Plasma Growth	-	-	6.14%	15.11%	7.05%	-22.89%	3.22%	31.83%	0.30%	-5.30%
Blood Center	311.06M	303.89M	284.9M	269.2M	252.83M	239.61M	236.16M	226.82M	278.96M	261.12M
Blood Center Growth	-	-2.31%	-6.25%	-5.51%	-6.08%	-5.23%	-1.44%	-3.95%	22.99%	-6.39%
Cell Processing	-	105.38M	107.56M	-	-	-	-	-	-	-
Cell Processing Growth	-	-	2.07%	-	-	-	-	-	-	-
Hemostasis Management	-	66.12M	75.5M	-	-	-	-	-	-	-
Hemostasis Management Growth	-	-	14.19%	-	-	-	-	-	-	-
Disposables Revenue	784.45M	-	-	-	-	-	-	-	-	-
Disposables Revenue Growth	-	-	-	-	-	-	-	-	-	-
Plasma Disposables	348.79M	-	-	-	-	-	-	-	-	-
Plasma Disposables Growth	-	-	-	-	-	-	-	-	-	-
Platelet	143.27M	-	-	-	-	-	-	-	-	-
Platelet Growth	-	-	-	-	-	-	-	-	-	-
Whole Blood	128.53M	-	-	-	-	-	-	-	-	-
Whole Blood Growth	-	-	-	-	-	-	-	-	-	-
Software Solutions	72.43M	-	-	-	-	-	-	-	-	-
Software Solutions Growth	-	-	-	-	-	-	-	-	-	-
Surgical	59.9M	-	-	-	-	-	-	-	-	-
Surgical Growth	-	-	-	-	-	-	-	-	-	-
Equipment and Other Related	51.94M	-	-	-	-	-	-	-	-	-
Equipment and Other Related Growth	-	-	-	-	-	-	-	-	-	-
Diagnostics	50.88M	-	-	-	-	-	-	-	-	-
Diagnostics Growth	-	-	-	-	-	-	-	-	-	-
Red Cell	39.26M	-	-	-	-	-	-	-	-	-
Red Cell Growth	-	-	-	-	-	-	-	-	-	-
OrthoPAT	13.82M	-	-	-	-	-	-	-	-	-
OrthoPAT Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	519.44M	522.69M	548.73M	606.85M	646.2M	522.61M	639.32M	842.9M	970.01M	1.01B
UNITED STATES Growth	-	0.62%	4.98%	10.59%	6.49%	-19.13%	22.33%	31.84%	15.08%	4.22%
Europe	187.72M	166.01M	164.23M	164.5M	153.35M	159.08M	163.52M	156.68M	160.14M	175.66M
Europe Growth	-	-11.57%	-1.07%	0.17%	-6.78%	3.74%	2.79%	-4.18%	2.21%	9.69%
Asia	111.76M	109.86M	115.13M	118.7M	109.3M	105.82M	110.8M	104.14M	107.54M	92.31M
Asia Growth	-	-1.70%	4.80%	3.10%	-7.92%	-3.18%	4.71%	-6.02%	3.27%	-14.16%
JAPAN	81.41M	79.27M	67.32M	69.91M	72.22M	77.68M	75.56M	61.3M	58.09M	62.41M
JAPAN Growth	-	-2.63%	-15.07%	3.85%	3.30%	7.56%	-2.72%	-18.88%	-5.23%	7.44%
Other Country or Region	8.5M	8.3M	8.52M	7.62M	7.42M	5.28M	3.99M	3.65M	13.28M	19.54M
Other Country or Region Growth	-	-2.34%	2.66%	-10.54%	-2.72%	-28.75%	-24.47%	-8.45%	263.62%	47.09%

Frequently Asked Questions

Valuation & Price

Haemonetics Corporation (HAE) has a price-to-earnings (P/E) ratio of 22.4x. This is roughly in line with market averages.

Growth & Financials

Haemonetics Corporation (HAE) reported $1.33B in revenue for fiscal year 2025. This represents a 82% increase from $727.8M in 2012.

Haemonetics Corporation (HAE) grew revenue by 4.0% over the past year. Growth has been modest.

Yes, Haemonetics Corporation (HAE) is profitable, generating $168.2M in net income for fiscal year 2025 (12.3% net margin).

Dividend & Returns

Haemonetics Corporation (HAE) has a return on equity (ROE) of 18.8%. This is reasonable for most industries.

Haemonetics Corporation (HAE) generated $256.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...